Systemic therapy for bone sarcomas

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Orthopaedic Practice

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/BCO.0000000000000442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting

  2016cited by this paper
• Giant Cell Tumor of Bone - An Overview.

  2016cited by this paper
• Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma

  2015cited by this paper
• Ifosfamide dose‐intensification for patients with metastatic Ewing sarcoma

  2015cited by this paper
• Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults

  2015cited by this paper
• Targeted therapies for advanced Ewing sarcoma family of tumors.

  2015cited by this paper
• Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial

  2015cited by this paper
• Ewing Sarcoma: Current Management and Future Approaches Through Collaboration.

  2015cited by this paper
• Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

  2015cited by this paper
• Chemotherapy for bone sarcomas in adults: the MD anderson experience.

  2015cited by this paper
• Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

  2015cited by this paper
• Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.

  2015cited by this paper
• Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years

  2015cited by this paper
• Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone

  2015cited by this paper
• Novel targeted therapies in chordoma: an update

  2015cited by this paper
• A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors

  2014cited by this paper
• Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.

  2014cited by this paper
• The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma

  2014cited by this paper
• EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment

  2014cited by this paper
• The value of high‐dose chemotherapy in patients with first relapsed Ewing sarcoma

  2014cited by this paper
• Nonoperative management of patients with carcinoma metastatic to bone

  2014cited by this paper
• MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1 (Paper 032)

  2014cited by this paper
• Phase II study on lapatinib in advanced EGFR-positive chordoma.

  2013cited by this paper
• Advanced chondrosarcomas: role of chemotherapy and survival.

  2013cited by this paper
• Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

  2013cited by this paper
• Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients

  2012cited by this paper
• Chordoma: current concepts, management, and future directions.

  2012cited by this paper
• Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone

  2012cited by this paper
• Phase II study of imatinib in advanced chordoma.

  2012cited by this paper
• Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

  2012cited by this paper
• Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.

  2012cited by this paper
• Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

  2010cited by this paper
• Interferon Alfa-2b for Recurrent and Metastatic Giant Cell Tumor of the Spine: Report of Two Cases

  2010cited by this paper
• Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.

  2010cited by this paper
• Response to high‐dose ifosfamide in patients with advanced/recurrent Ewing sarcoma

  2009cited by this paper
• Response to imatinib plus sirolimus in advanced chordoma.

  2009cited by this paper
• The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975–2004)

  2009cited by this paper
• Response to erlotinib in a patient with treatment refractory chordoma.

  2009cited by this paper
• Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan‐Kettering experience

  2009cited by this paper
• Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

  2009cited by this paper
• Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib

  2009cited by this paper
• Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients

  2009cited by this paper
• Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel

  2009cited by this paper
• Osteosarcoma incidence and survival rates from 1973 to 2004

  2009cited by this paper
• A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma

  2008cited by this paper
• Treatment options for recurrent giant cell tumors of bone

  2008cited by this paper
• Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to IM in advanced chordoma

  2007cited by this paper
• Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

  2007cited by this paper
• Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors

  2006cited by this paper
• Histologically verified lung metastases in benign giant cell tumours—14 cases from a single institution

  2006cited by this paper
• Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience

  2005cited by this paper
• Management of bone metastases in cancer: a review.

  2005cited by this paper
• Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.

  2005cited by this paper
• Giant cell tumor of bone

  2004cited by this paper
• Imatinib mesylate in chordoma

  2004cited by this paper
• Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

  2003cited by this paper
• Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival.

  2003cited by this paper
• Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Chest Wall: Impact of Initial Versus Delayed Resection on Tumor Margins, Survival, and Use of Radiation Therapy

  2003cited by this paper
• Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

  2003cited by this paper
• Dedifferentiated chordoma: Response to aggressive chemotherapy in two cases

  1993cited by this paper
• Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study.

  1990cited by this paper
• Chordoma: Natural history and treatment results in 33 cases

  1988cited by this paper
• Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.

  1988cited by this paper
• Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults.

  1987cited by this paper
• The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

  1986cited by this paper
• Chordoma. A clinicopathologic study of metastasis.

  1979cited by this paper
• EWING'S SARCOMA.

  1964cited by this paper
• Biologics: Targets and Therapy Dovepress Giant-cell Tumor of Bone: Treatment Options and Role of Denosumab

  year unknowncited by this paper

• Canadian consensus on TRK‐inhibitor therapy for NTRK fusion‐positive sarcoma

  2021cites this paper